Clinicopathological Significance of Plasminogen Activator Inhibitor-1 Promoter 4G/5G Polymorphism in Breast Cancer: A Meta-analysis

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background and Aims: Plasminogen activator inhibitor type 1 (PAI-1) is associated with poor prognosis in breast cancer. Transcriptional expression of the . PAI-1 can be controlled by . PAI-1 promoter 4G/5G polymorphism. However, the significance of . PAI-1 promoter 4G/5G polymorphism in breast cancer patients is contentious. To address this controversy, we conducted a meta-analysis for the relationships between . PAI-1 promoter polymorphism and clinicopathological characteristics of breast cancer. Methods: Relevant published studies were identified using a search of PubMed, Embase, and the ISI Web of Science. The effect sizes of . PAI-1 promoter 4G/5G polymorphism on breast cancer risk, lymph node metastasis, histologic grade, and overall survival were calculated by odds ratio (OR) or hazard ratio. The effect sizes were combined using a random-effects model. Results: Individuals with 4G/4G genotype had a higher risk of breast cancer than those with the combined 4G/5G and 5G/5G genotypes (OR = 1.388; . p = 0.031). Breast cancer patients with the 5G/5G genotype displayed lymph node metastasis more than patients with either the combined other genotypes (OR = 1.495; . p = 0.027) or with the 4G/4G genotype (OR = 1.623; . p = 0.018). However, the . PAI-1 promoter 4G/5G polymorphism was not associated with histological grade or overall survival. Conclusions: PAI-1 promoter 4G/5G polymorphism is associated with a relatively increased risk of breast cancer development and lymph node metastasis.

Original languageEnglish
Pages (from-to)39-45
Number of pages7
JournalArchives of Medical Research
Volume44
Issue number1
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Plasminogen Activator Inhibitor 1
Meta-Analysis
Breast Neoplasms
Genotype
Odds Ratio
Lymph Nodes
Neoplasm Metastasis
Survival
PubMed

Keywords

  • Breast cancer
  • Meta-analysis
  • PAI-1
  • Polymorphism

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{d27b32ed6dc644d9b3e15109a3caf4b7,
title = "Clinicopathological Significance of Plasminogen Activator Inhibitor-1 Promoter 4G/5G Polymorphism in Breast Cancer: A Meta-analysis",
abstract = "Background and Aims: Plasminogen activator inhibitor type 1 (PAI-1) is associated with poor prognosis in breast cancer. Transcriptional expression of the . PAI-1 can be controlled by . PAI-1 promoter 4G/5G polymorphism. However, the significance of . PAI-1 promoter 4G/5G polymorphism in breast cancer patients is contentious. To address this controversy, we conducted a meta-analysis for the relationships between . PAI-1 promoter polymorphism and clinicopathological characteristics of breast cancer. Methods: Relevant published studies were identified using a search of PubMed, Embase, and the ISI Web of Science. The effect sizes of . PAI-1 promoter 4G/5G polymorphism on breast cancer risk, lymph node metastasis, histologic grade, and overall survival were calculated by odds ratio (OR) or hazard ratio. The effect sizes were combined using a random-effects model. Results: Individuals with 4G/4G genotype had a higher risk of breast cancer than those with the combined 4G/5G and 5G/5G genotypes (OR = 1.388; . p = 0.031). Breast cancer patients with the 5G/5G genotype displayed lymph node metastasis more than patients with either the combined other genotypes (OR = 1.495; . p = 0.027) or with the 4G/4G genotype (OR = 1.623; . p = 0.018). However, the . PAI-1 promoter 4G/5G polymorphism was not associated with histological grade or overall survival. Conclusions: PAI-1 promoter 4G/5G polymorphism is associated with a relatively increased risk of breast cancer development and lymph node metastasis.",
keywords = "Breast cancer, Meta-analysis, PAI-1, Polymorphism",
author = "Ju-Han Lee and Younghye Kim and Jung-Woo Choi and Kim, {Young Sik}",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.arcmed.2012.12.002",
language = "English",
volume = "44",
pages = "39--45",
journal = "Archives of Medical Research",
issn = "0188-4409",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Clinicopathological Significance of Plasminogen Activator Inhibitor-1 Promoter 4G/5G Polymorphism in Breast Cancer

T2 - A Meta-analysis

AU - Lee, Ju-Han

AU - Kim, Younghye

AU - Choi, Jung-Woo

AU - Kim, Young Sik

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background and Aims: Plasminogen activator inhibitor type 1 (PAI-1) is associated with poor prognosis in breast cancer. Transcriptional expression of the . PAI-1 can be controlled by . PAI-1 promoter 4G/5G polymorphism. However, the significance of . PAI-1 promoter 4G/5G polymorphism in breast cancer patients is contentious. To address this controversy, we conducted a meta-analysis for the relationships between . PAI-1 promoter polymorphism and clinicopathological characteristics of breast cancer. Methods: Relevant published studies were identified using a search of PubMed, Embase, and the ISI Web of Science. The effect sizes of . PAI-1 promoter 4G/5G polymorphism on breast cancer risk, lymph node metastasis, histologic grade, and overall survival were calculated by odds ratio (OR) or hazard ratio. The effect sizes were combined using a random-effects model. Results: Individuals with 4G/4G genotype had a higher risk of breast cancer than those with the combined 4G/5G and 5G/5G genotypes (OR = 1.388; . p = 0.031). Breast cancer patients with the 5G/5G genotype displayed lymph node metastasis more than patients with either the combined other genotypes (OR = 1.495; . p = 0.027) or with the 4G/4G genotype (OR = 1.623; . p = 0.018). However, the . PAI-1 promoter 4G/5G polymorphism was not associated with histological grade or overall survival. Conclusions: PAI-1 promoter 4G/5G polymorphism is associated with a relatively increased risk of breast cancer development and lymph node metastasis.

AB - Background and Aims: Plasminogen activator inhibitor type 1 (PAI-1) is associated with poor prognosis in breast cancer. Transcriptional expression of the . PAI-1 can be controlled by . PAI-1 promoter 4G/5G polymorphism. However, the significance of . PAI-1 promoter 4G/5G polymorphism in breast cancer patients is contentious. To address this controversy, we conducted a meta-analysis for the relationships between . PAI-1 promoter polymorphism and clinicopathological characteristics of breast cancer. Methods: Relevant published studies were identified using a search of PubMed, Embase, and the ISI Web of Science. The effect sizes of . PAI-1 promoter 4G/5G polymorphism on breast cancer risk, lymph node metastasis, histologic grade, and overall survival were calculated by odds ratio (OR) or hazard ratio. The effect sizes were combined using a random-effects model. Results: Individuals with 4G/4G genotype had a higher risk of breast cancer than those with the combined 4G/5G and 5G/5G genotypes (OR = 1.388; . p = 0.031). Breast cancer patients with the 5G/5G genotype displayed lymph node metastasis more than patients with either the combined other genotypes (OR = 1.495; . p = 0.027) or with the 4G/4G genotype (OR = 1.623; . p = 0.018). However, the . PAI-1 promoter 4G/5G polymorphism was not associated with histological grade or overall survival. Conclusions: PAI-1 promoter 4G/5G polymorphism is associated with a relatively increased risk of breast cancer development and lymph node metastasis.

KW - Breast cancer

KW - Meta-analysis

KW - PAI-1

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=84873181247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873181247&partnerID=8YFLogxK

U2 - 10.1016/j.arcmed.2012.12.002

DO - 10.1016/j.arcmed.2012.12.002

M3 - Article

C2 - 23291383

AN - SCOPUS:84873181247

VL - 44

SP - 39

EP - 45

JO - Archives of Medical Research

JF - Archives of Medical Research

SN - 0188-4409

IS - 1

ER -